TY - JOUR
T1 - The resilience of adolescent male rats to acute stress-induced delayed anxiety is age-related and glucocorticoid release-dependent
AU - Campos-Cardoso, Rodrigo
AU - Novaes, Leonardo Santana
AU - Godoy, Lívea Dornela
AU - dos Santos, Nilton Barreto
AU - Perfetto, Juliano Genaro
AU - Lazarini-Lopes, Willian
AU - Garcia-Cairasco, Norberto
AU - Padovan, Cláudia Maria
AU - Munhoz, Carolina Demarchi
N1 - Publisher Copyright:
© 2022
PY - 2023/3/15
Y1 - 2023/3/15
N2 - Studies investigated how stressful experiences modulate physiological and behavioral responses and the consequences of stress-induced corticosterone release in anxiety-like behavior. Adolescence is crucial to brain maturation, and several neurobiological changes in this period lead individuals to increased susceptibility or resilience to aversive situations. Despite the effects of stress in adults, information about adolescents' responses to acute stress is lacking. We aimed to understand how adolescence affects acute stress responses. Male adolescent rats (30 days old) were 2 h restrained, and anxiety-like behaviors were measured immediately or 10 days after stress in the elevated plus-maze (EPM) and the light-dark box (LDB) tests. To verify the importance of CORT modulation in stress-induced anxiety, another group of rats was treated, 30 min before restraint, with metyrapone to blunt the stress-induced CORT peak and tested immediately after stress. To show that stress effects on behavior were age-dependent, another set of rats was tested in two different periods – early adolescence (30 days old) and mid-adolescence (40 days old) and were treated or not with metyrapone before the stress session and tested immediately or ten days later in the LDB test. Only early adolescent male rats were resilient to delayed anxiety-like behavior in EPM and LDB tests. Metyrapone treatment increased the rats' exploration immediately and ten days after stress. These data suggest a specific age at which adolescent rats are resilient to the delayed effects of acute restraint stress and that the metyrapone treatment has long-term behavioral consequences.
AB - Studies investigated how stressful experiences modulate physiological and behavioral responses and the consequences of stress-induced corticosterone release in anxiety-like behavior. Adolescence is crucial to brain maturation, and several neurobiological changes in this period lead individuals to increased susceptibility or resilience to aversive situations. Despite the effects of stress in adults, information about adolescents' responses to acute stress is lacking. We aimed to understand how adolescence affects acute stress responses. Male adolescent rats (30 days old) were 2 h restrained, and anxiety-like behaviors were measured immediately or 10 days after stress in the elevated plus-maze (EPM) and the light-dark box (LDB) tests. To verify the importance of CORT modulation in stress-induced anxiety, another group of rats was treated, 30 min before restraint, with metyrapone to blunt the stress-induced CORT peak and tested immediately after stress. To show that stress effects on behavior were age-dependent, another set of rats was tested in two different periods – early adolescence (30 days old) and mid-adolescence (40 days old) and were treated or not with metyrapone before the stress session and tested immediately or ten days later in the LDB test. Only early adolescent male rats were resilient to delayed anxiety-like behavior in EPM and LDB tests. Metyrapone treatment increased the rats' exploration immediately and ten days after stress. These data suggest a specific age at which adolescent rats are resilient to the delayed effects of acute restraint stress and that the metyrapone treatment has long-term behavioral consequences.
KW - Elevated plus maze
KW - HPA-Axis
KW - Light-dark box
KW - Metyrapone
KW - Restraint stress
UR - http://www.scopus.com/inward/record.url?scp=85146467424&partnerID=8YFLogxK
U2 - 10.1016/j.neuropharm.2022.109385
DO - 10.1016/j.neuropharm.2022.109385
M3 - Article
C2 - 36603798
AN - SCOPUS:85146467424
SN - 0028-3908
VL - 226
JO - Neuropharmacology
JF - Neuropharmacology
M1 - 109385
ER -